Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines

The large size of poxvirus genomes has stymied attempts to identify determinants recognized by CD8+ T cells and greatly impeded development of mouse smallpox vaccination models. Here, we use a vaccinia virus (VACV) expression library containing each of the predicted 258 open reading frames to identify five peptide determinants that account for approximately half of the VACV-specific CD8+ T cell response in C57BL/6 mice. We show that the primary immunodominance hierarchy is greatly affected by the route of VACV infection and the poxvirus strain used. Modified vaccinia virus ankara (MVA), a candidate replacement smallpox vaccine, failed to induce responses to two of the defined determinants. This could not be predicted by genomic comparison of viruses and is not due strictly to limited MVA replication in mice. Several determinants are immunogenic in cowpox and ectromelia (mousepox) virus infections, and immunization with the immunodominant determinant provided significant protection against lethal mousepox. These findings have important implications for understanding poxvirus immunity in animal models and bench-marking immune responses to poxvirus vaccines in humans.

[1]  J. Marchal Infectious Ectromelia. A hitherto Undescribed Virus Disease of Mice. , 1930 .

[2]  R. F. Parker,et al.  FURTHER STUDIES OF THE INFECTIOUS UNIT OF VACCINIA , 1941, The Journal of experimental medicine.

[3]  F. Burnet,et al.  The relationship between the virus of infectious ectromelia of mice and vaccinia virus. , 1946, Journal of immunology.

[4]  F. Fenner,et al.  Studies in infectious ectromelia of mice; immunization of mice against ectromelia with living vaccinia virus. , 1947, The Australian journal of experimental biology and medical science.

[5]  F. Fenner,et al.  The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice. , 1948, Lancet.

[6]  F. Fenner,et al.  Mouse-pox; infectious ectromelia of mice; a review. , 1949, Journal of immunology.

[7]  R. Blanden MECHANISMS OF RECOVERY FROM A GENERALIZED VIRAL INFECTION: MOUSEPOX , 1971, The Journal of experimental medicine.

[8]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[9]  B. Moss,et al.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype , 1985, Nature.

[10]  F. Fenner Smallpox and its eradication , 1988 .

[11]  E. Coligan Current protocols in immunology , 1991 .

[12]  B. Moss,et al.  Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein , 1991, Journal of virology.

[13]  Li Wu,et al.  The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells , 1992, The Journal of experimental medicine.

[14]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Karupiah,et al.  Importance of interferons in recovery from mousepox , 1993, Journal of virology.

[16]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[17]  A. Vitiello,et al.  Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. , 1996, Journal of immunology.

[18]  G. Karupiah,et al.  Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection , 1996, Journal of virology.

[19]  C. Mims The Pathogenesis of the Acute Exanthems , 1996 .

[20]  B. Moss,et al.  Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis , 1996, Journal of virology.

[21]  K. Rock,et al.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. , 1997, Journal of immunology.

[22]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[23]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[24]  J. Sidney,et al.  Conserved MHC Class I Peptide Binding Motif Between Humans and Rhesus Macaques1 , 2000, The Journal of Immunology.

[25]  J. Ramírez,et al.  Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.

[26]  D. Smee,et al.  Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. , 2000, The Journal of infectious diseases.

[27]  W Chen,et al.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. , 2000, Immunity.

[28]  S. Fields,et al.  Genome-wide analysis of vaccinia virus protein-protein interactions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  John Sidney,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.

[30]  Anthony S. Fauci,et al.  Bioterrorism: A clear and present danger , 2001, Nature Medicine.

[31]  J. Yewdell,et al.  Inhibitory Effects of Cytomegalovirus Proteins US2 and US11 Point to Contributions from Direct Priming and Cross-Priming in Induction of Vaccinia Virus-Specific CD8+ T Cells , 2002, The Journal of Immunology.

[32]  A. Rothman,et al.  Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. , 2002, The Journal of infectious diseases.

[33]  Hans-Georg Rammensee,et al.  Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[35]  John Cruz,et al.  Quantitation of CD8+ T Cell Responses to Newly Identified HLA-A*0201–restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses , 2003, The Journal of experimental medicine.

[36]  Rachel L. Roper,et al.  Poxvirus Orthologous Clusters: toward Defining the Minimum Essential Poxvirus Genome , 2003, Journal of Virology.

[37]  J. Berzofsky,et al.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Karupiah,et al.  Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. M. Belyakov,et al.  Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses , 2004, Journal of Virology.

[40]  B. Graham,et al.  Modified vaccinia Ankara: potential as an alternative smallpox vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  G. Carcelain,et al.  Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-γ–producing T Cell Memory to Smallpox in Humans , 2004, The Journal of experimental medicine.

[42]  Aaron J. Johnson,et al.  Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice 1 , 2004, The Journal of Immunology.

[43]  P. Earl,et al.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Earl,et al.  Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox , 2004, Nature.